If funding is found, PaMZ will move to Phase III tests by the end of the year, their backers, TB Alliance, said.
PaMZ comprises two candidate drugs that are not yet licensed for use against TB, called Pa-824 and moxifloxacin, deployed with an existing treatment, pyrazinamide.
The trial reported at the 20th International AIDS Conference in Melbourne entailed testing PaMZ against standard drugs - isoniazid, rifampicin, pyrazinamide and ethambutol - among 207 volunteers in South Africa, a fifth of whom were co-infected with HIV.
Of these, 181 were sensitive to the PaMZ drugs while 26 were multidrug-resistant (MDR), meaning that they had failed to respond to conventional antibiotics.
It found that 71 percent of people treated with PaMZ were cleared of TB bacteria in their sputum within two months.